Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Projected to Post Quarterly Earnings on Monday

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) is expected to announce its results after the market closes on Monday, October 26th. Analysts expect Shionogi & Co., Ltd. Unsponsored ADR to announce earnings of $0.13 per share and revenue of $1.11 billion for the quarter.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.18. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%. On average, analysts expect Shionogi & Co., Ltd. Unsponsored ADR to post $0.82 EPS for the current fiscal year and $0.79 EPS for the next fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

OTCMKTS SGIOY opened at $9.61 on Friday. The company has a current ratio of 1.14, a quick ratio of 1.00 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $9.13 and a 200 day simple moving average of $9.21. Shionogi & Co., Ltd. Unsponsored ADR has a 12 month low of $7.83 and a 12 month high of $12.00. The firm has a market capitalization of $16.36 billion, a P/E ratio of 9.61, a PEG ratio of 3.45 and a beta of 0.08.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on SGIOY shares. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 15th. Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Three analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat.com, the stock presently has a consensus rating of “Strong Buy”.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a longstanding focus on infectious diseases and specialty therapies.

Its products and development programs have included Xofluza (baloxavir marboxil), an oral treatment for influenza; Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat Gram-negative bacterial infections; and medicines for central nervous system disorders, pain and other therapeutic areas.